Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest PEGylation Stories

2012-03-28 02:24:51

SAN FRANCISCO, March 28, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today reported that its partner Affymax, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. Nektar and Affymax have an exclusive agreement under which Nektar provides Affymax with its proprietary PEGylation technology for use in OMONTYS®....

2012-03-20 06:26:10

SAN FRANCISCO, March 20, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that the company is consolidating its U.S.-based research scientists at the company's existing San Francisco state-of-the-art R&D center, which is located adjacent to the UCSF research and medical campus in Mission Bay. With the consolidation, research scientists from Nektar's Huntsville, Alabama research site will be relocating to San Francisco. Nektar's San Francisco R&D...

2012-02-29 09:29:00

SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in pediatric patients with emphasis on leukemia, lymphoma and sarcoma cancers. These three cancers represent approximately 50% of all cancers that occur in the pediatric population. Patients with advanced cancers who have failed current therapy will be...

2012-02-24 18:30:00

SAN FRANCISCO, Calif., Feb. 24, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter ended December 31, 2011 on Wednesday, February 29, 2012, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). The press release and a live audio-only Webcast of the conference...

2012-02-23 15:05:00

EAST BRUNSWICK, N.J., Feb. 23, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Cowen and Company 32(nd) Annual Health Care Conference on Tuesday, March 6, 2012 at 10:40 AM Eastern Time. The conference will be held at the Boston Marriott Copley Place in Boston, MA. A live webcast of the presentation can be accessed through the investor...

2012-02-17 15:05:00

EAST BRUNSWICK, N.J., Feb. 17, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Citi 2012 Global Health Care Conference on Tuesday, February 28, 2012 at 8:30 AM Eastern Time. The conference will be held at the Waldorf Astoria Hotel in New York City. A live webcast of the presentation can be accessed through the investor relations section of the...

2012-02-08 15:05:00

EAST BRUNSWICK, N.J., Feb. 8, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, February 15, 2012 at 2:00 PM Eastern Time. The conference will be held at the Waldorf Astoria in New York City. A live webcast of the presentation can be accessed through the investor relations section of the...

2012-02-02 03:30:00

LANGHORNE, Pennsylvania and OXFORD, England, February 2, 2012 /PRNewswire/ -- EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has acquired the exclusive worldwide development and commercialization rights to ASPAREC(R) for the treatment of acute lymphoblastic leukemia (ALL) from Alize Pharma. Under the terms of the agreement, EUSA will pay Alize Pharma an upfront fee, regulatory...

2012-01-04 17:26:00

SAN FRANCISCO, Jan. 4, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 30th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Wednesday, January 11, 2012 at 8:30 a.m. Pacific time. The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website:...

2011-12-15 07:00:00

SOUTH PLAINFIELD, N.J., Dec. 15, 2011 /PRNewswire/ -- Prolong Pharmaceuticals today announced that Tom Flachmeyer has joined Prolong to spearhead the firms' engineering and facilities planning function for it oxygen therapeutic product SANGUINATE(TM). Having previously directed the construction of the world's largest biotech facility to date, Wyeth's Grange Castle facility in Dublin, Ireland, Flachmeyer is charged with expanding Prolong's current cGMP production facility to support...